Anlon Healthcare Limited has announced a strategic move to strengthen its position in the pharmaceutical intermediates market. The company has entered into a Share Purchase Agreement (SPA) to acquire a controlling stake in Apiqo Organics Private Limited, a move that aims to enhance its vertical integration and manufacturing capabilities.

Key Acquisition Details

Strategic Implications

The acquisition of Apiqo Organics is expected to bring several strategic benefits to Anlon Healthcare:

1. Vertical Integration: The move aims to enhance Anlon's vertical integration, potentially improving its supply chain efficiency and cost structure.

2. Manufacturing Capacity: The deal is set to add an additional 700-800 MT of annual manufacturing capacity for advanced pharmaceutical intermediates to Anlon's portfolio.

3. Supply Security: By acquiring Apiqo, Anlon seeks to secure a critical supply of high-quality intermediates, which could lead to more reliable production processes.

4. Market Position: The acquisition is expected to strengthen Anlon's position as a more agile, cost-competitive, and reliable partner for both innovator and generic pharmaceutical companies worldwide.

About Apiqo Organics

Apiqo Organics Private Limited, formerly known as M/s Apple Life Science, is engaged in manufacturing pharmaceutical intermediates, industrial and fine chemicals, and inorganic chemicals. The company was incorporated on December 1, 2025, following its conversion from a partnership firm to a private limited company.

Financial Snapshot of Apiqo Organics

Transaction Timeline

The acquisition is subject to customary closing conditions as outlined in the SPA. It is expected to be completed within three months from the date of signing the agreement, or as mutually agreed upon by the parties involved.

Regulatory Compliance

This disclosure has been made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The strategic acquisition by Anlon Healthcare demonstrates the company's commitment to growth and its focus on strengthening its position in the pharmaceutical intermediates market. By securing a critical supply chain component and expanding its manufacturing capabilities, Anlon aims to better serve the global pharmaceutical industry's needs.

Anlon Healthcare Limited has reported impressive financial results for the quarter ended September 30, 2025, demonstrating significant growth across key metrics.

Financial Highlights

The company's Q2 FY26 performance shows substantial year-over-year improvements:

• Total income rose 116% to INR 52.32 crore
• Profit after tax (PAT) increased nearly 4 times to INR 9.32 crore
• Revenue from operations grew 37.8% to INR 33.29 crore, up from INR 24.17 crore in the previous year's quarter

Half-Year Performance

For the half-year period:

• Revenue reached INR 61.99 crore, up from INR 53.56 crore in the previous period
• Profit after tax increased to INR 12.86 crore, compared to INR 6.36 crore previously

Company Overview

Anlon Healthcare Limited, a pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and drug intermediates, has been listed on the stock exchanges since September 3, 2025.

Financial Position

• Total assets increased to INR 287.52 crore from INR 188.48 crore as of March 31, 2025
• The company has utilized INR 82.45 crore from its IPO proceeds of INR 121.03 crore, with INR 38.58 crore remaining unutilized

Future Plans

Anlon Healthcare is planning expansion to meet growing demand:

• A 700 metric ton greenfield expansion is in progress
• The company is exploring inorganic acquisitions to enhance its capabilities
• Anlon Healthcare aims to achieve a 30% revenue CAGR over the next three years, with a focus on regulated markets

The company's quarterly results are attributed to strong operating leverage and an improved business mix. Anlon Healthcare's Q2 performance reflects its position in the market and its ability to capitalize on growth opportunities. The increase in revenue and profit demonstrates the company's strategies and the market demand for its products.